« Back to Record
Citation APA

Voit, T., Topaloglu, H., Straub, V., Muntoni, F., Deconinck, N., Campion, G., De Kimpe, S. J., Eagle, M., Guglieri, M., Hood, S., Liefaard, L., Lourbakos, A., Morgan, A., Nakielny, J., Quarcoo, N., Ricotti, V., Rolfe, K., Servais, L., Wardell, C., Wilson, R., Wright, P., & Kraus, J. E. (2014). Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. Lancet neurology, 13(10), 987-996. doi:10.1016/S1474-4422(14)70195-4


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/185496

Voit, T., Topaloglu, H., Straub, V., Muntoni, F., Deconinck, N., Campion, G., De Kimpe, S. J., Eagle, M., Guglieri, M., Hood, S., Liefaard, L., Lourbakos, A., Morgan, A., Nakielny, J., Quarcoo, N., Ricotti, V., Rolfe, K., Servais, L., Wardell, C., Wilson, R., Wright, P., & Kraus, J. E. (2014). Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. Lancet neurology, 13(10), 987-996. doi:10.1016/S1474-4422(14)70195-4